Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 5-Year Mandatory Stable Supply Rule for Generics under Scrutiny: Expert Panel
February 16, 2023
- Darzquro to Escape CEA-Based Price Tweaks, Padcev Faces Cuts
February 16, 2023
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
- PM Vows Collab with Pharma for Drug Discovery; Health Minister on Relyvrio
February 16, 2023
- Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
February 15, 2023
- Label Revisions Ordered for GLP-1 Agents to Add New Side Effect Risks
February 15, 2023
- Japan Should Create Drug Discovery Command Tower: Chugai Honorary Chair
February 14, 2023
- Trade Group Calls for Predictability around SaMD Reimbursement: LDP Gathering
February 14, 2023
- J-TEC’s Cell Sheet for Vitiligo Now in Line for Approval in Japan
February 14, 2023
- Japan Extends Paxlovid Shelf Life to 24 Months
February 13, 2023
- Japan Ends Supply of Moderna’s Original COVID Vaccine
February 13, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
February 13, 2023
- Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
February 10, 2023
- Pharma Trade Groups Stress Concern for Re-Pricing Debate over Xocova: Chuikyo
February 9, 2023
- Japan Panel OKs Next COVID Vaccine Rollout This Autumn, Winter
February 9, 2023
- Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- MHLW Council’s Efforts to Address Drug Lag Led to 371 Approvals to Date: Minister
February 8, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…